EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma

Haoyu Zhang, Jiaqi Tan iD, Xiaoqiao Cui, Xueying Wang, Gangcai Zhu iD, Zhaoyu Pan iD, Yunyun Wang, Kaibin Song iD

Immunology · 2026-12 · 179 (4) · 695-708

DOI: 10.1111/imm.70196 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Immunology, online erschienen am 09.09.2026. Verfasst von Haoyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha City, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Nasopharyngeal Carcinoma, Body Mass Index, Nasopharyngeal Neoplasms. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Harbin Medical University Cancer Hospital, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the associations of body mass index (BMI) and metabolic syndrome (MetS) with outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M‐NPC) receiving anti‐PD‐1 therapy, and to develop a prognostic model for overall survival (OS). This multicenter retrospective study included 238 patients with BMI ≥ 18.5 kg/m 2 from two Chinese hospitals. BMI and MetS associations were evaluated using center‐adjusted, center‐stratified, hierarchical, and quantitative sensitivity analyses. An OS nomogram was developed in the Xiangya cohort and externally evaluated in the Harbin cohort. In clinical confounder‐adjusted models with the exposures entered separately, high BMI was associated with OS (HR, 0.462; 95% CI, 0.324–0.657) and PFS (HR, 0.511; 95% CI, 0.380–0.688), and MetS was associated with OS (HR, 0.433; 95% CI, 0.278–0.674) and PFS (progression‐free survival) (HR, 0.616; 95% CI, 0.439–0.866). When BMI and MetS were jointly modelled, the MetS‐PFS association was attenuated (HR, 0.714; 95% CI, 0.504–1.012; p = 0.058). Exploratory biomarker analyses revealed group differences in combined positive score (CPS) and pan‐immune‐inflammation value (PIV). Center‐specific effect directions were consistent, but the external‐center calibration slope was 0.53 (95% CI, 0.08–0.98). Among anti‐PD‐1‐treated Chinese patients with R/M‐NPC and a BMI ≥ 18.5 kg/m 2 , higher BMI and MetS showed prognostic associations. These observational data do not establish causal or treatment‐predictive effects, and prospective validation in non‐Chinese populations across the full body‐weight spectrum is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeNasopharyngeal CarcinomaBody Mass IndexNasopharyngeal NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansFemaleMalePrognosisRetrospective StudiesMiddle AgedNeoplasm Recurrence, LocalAdultTreatment OutcomeChinaAgedNeoplasm MetastasisNomograms

Stichwörter der Autor:innen

body mass indeximmunotherapymetabolic syndromenomogramprognosisrecurrent/metastatic nasopharyngeal carcinoma

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha City, China.
  • Department of Otorhinolaryngology Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
  • Department of Otorhinolaryngology Head and Neck Surgery, Hunan Children's Hospital, Changsha City, China.

ORCID-Profile: Jiaqi Tan, Gangcai Zhu, Zhaoyu Pan, Kaibin Song

Förderung

  • Harbin Medical University Cancer Hospital
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Changsha Distinguished Young Scholars
  • The science and technology innovation Program of Hunan Province

Zitieren

APA

Zhang, H., Tan, J., Cui, X., Wang, X., Zhu, G., Pan, Z., Wang, Y., & Song, K. (2026). Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Immunology, 179(4), 695-708. https://doi.org/10.1111/imm.70196

Vancouver

Zhang H, Tan J, Cui X, Wang X, Zhu G, Pan Z, et al. Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Immunology. 2026;179(4):695-708. doi:10.1111/imm.70196

BibTeX
@article{Zhang2026,
  author = {Zhang, Haoyu and Tan, Jiaqi and Cui, Xiaoqiao and Wang, Xueying and Zhu, Gangcai and Pan, Zhaoyu and Wang, Yunyun and Song, Kaibin},
  title = {Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma},
  journal = {Immunology},
  year = {2026},
  volume = {179},
  number = {4},
  pages = {695--708},
  doi = {10.1111/imm.70196}
}
Kostenlos starten →